The Age
·general
·1 hour ago
Why ‘Big Pharma’ isn’t cashing in on the peptide craze
Big pharmaceutical companies are largely avoiding the booming illegal peptide market in Australia as they deem the products unsafe and unprofitable. Novo Nordisk's Ana Svensson stated that popular peptides like BPC-157 and Melanotan II lack the rigorous testing needed for safety and effectiveness. Experts emphasize that many of these peptides are still experimental and do not meet development standards.
Summary by Glance · The Age
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI